Compare Enveric Biosciences Inc (ENVB) vs Humana Inc (HUM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enveric Biosciences Inc vs Humana Inc — how do they compare? Enveric Biosciences Inc trades at $1.51 (market cap $6.80M), while Humana Inc trades at $440.25 (market cap $46.49B). The key difference: Humana Inc is far larger — about 6836.8× Enveric Biosciences Inc's market cap, and Humana Inc pays a 0.91% dividend while Enveric Biosciences Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Enveric Biosciences Inc for 14 Days and Humana Inc for 53 Days on average.
| ENVB | HUM | |
|---|---|---|
Market Cap | $6.80M | $46.49B |
Volume | 64,867 | 2,567,704 |
Sector | Health | Health |
52-Week High | $10.80 | $409.85 |
52-Week Low | $1.27 | $163.67 |
Typical Hold Time | 14 Days | 53 Days |
Enterprise Value | -$1.49M | $53.84B |
Dividend Yield | — | 0.91% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ENVB trades at $1.495 with a 1.7% daily gain, showing technical bearish signals despite recent earnings beats. The company reported no revenue in 2025 with significant losses (-$8.77M net income), though valuation metrics appear low (EV/EBITDA 0.17, P/B 0.84). Recent news highlights patent approvals and positive preclinical data for non-hallucinogenic therapeutics.
The outlook remains speculative given the lack of revenue and substantial losses, offset by strong analyst support (75% buy rating) and promising drug development progress. Key risks include funding needs and clinical trial outcomes, while institutional sentiment appears cautiously optimistic about long-term pipeline potential.
Humana (HUM) trades at $441.74, up 11.41% over 24 hours, reflecting strong momentum. The stock shows bullish technical signals with support at $391 and resistance at $406. Fundamentally, revenue grew to $129.66B in 2025, though net income margin compressed to 0.88%. Recent news highlights a Barclays upgrade to a $515 price target and upcoming Q3 earnings on November 6, 2026.
The outlook is cautiously optimistic with a consensus price target of $457.05 implying modest upside. Risks include margin pressure from Medicare Advantage plan changes and potential regulatory scrutiny. Institutional activity is mixed, with Bank of America adding a position while some funds reduced stakes.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Enveric Biosciences Inc
Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.
Read more on ENVB →About Humana Inc
Humana is one of the largest private health insurers in the U.S. with a focus on administering Medicare Advantage plans. The firm has built a niche specializing in government-sponsored programs, with nearly all its medical membership stemming from individual and group Medicare Advantage, Medicaid, and the military's Tricare program. The firm is also a leader in stand-alone prescription drug plans for seniors enrolled in traditional fee-for-service Medicare. Humana offers employer-based plans primarily for small businesses along with specialty insurance offerings such as dental, vision, and life. Beyond medical insurance, the company provides other healthcare services, including primary-care services, at-home services, and pharmacy benefit management.
Read more on HUM →
